Moderna Files 8-K: Financials & Reg FD Update
Ticker: MRNA · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1682852
| Field | Detail |
|---|---|
| Company | Moderna, Inc. (MRNA) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, regulation-fd, filing-update
Related Tickers: MRNA
TL;DR
Moderna filed an 8-K today for routine financial and Reg FD updates. No major news.
AI Summary
On September 12, 2024, Moderna, Inc. filed an 8-K report to disclose information regarding financial statements and exhibits, as well as a Regulation FD disclosure. The filing does not contain specific financial figures or new material events beyond routine disclosures.
Why It Matters
This 8-K filing serves as a routine update for investors, providing access to financial statements and ensuring compliance with Regulation FD disclosure requirements.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and Regulation FD disclosure, indicating no new material events or significant risks.
Key Players & Entities
- Moderna, Inc. (company) — Registrant
- September 12, 2024 (date) — Date of Report
- 325 Binney Street, Cambridge, MA 02142 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Moderna, Inc.?
The primary purpose of this 8-K filing is to disclose information regarding financial statements and exhibits, and to provide a Regulation FD disclosure.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 12, 2024.
What is Moderna, Inc.'s principal executive office address?
Moderna, Inc.'s principal executive office is located at 325 Binney Street, Cambridge, MA 02142.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What was Moderna's former company name?
Moderna's former company name was Moderna Therapeutics, Inc.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-12 06:03:14
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market
Filing Documents
- mrna-20240912.htm (8-K) — 28KB
- exhibit991-09122024.htm (EX-99.1) — 66KB
- 0001682852-24-000049.txt ( ) — 230KB
- mrna-20240912.xsd (EX-101.SCH) — 2KB
- mrna-20240912_lab.xml (EX-101.LAB) — 21KB
- mrna-20240912_pre.xml (EX-101.PRE) — 12KB
- mrna-20240912_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 12, 2024, Moderna, Inc. (the "Company") issued a press release providing research and development and business updates in connection with the Company's investor event on the same date. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Moderna, Inc. dated September 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 12, 2024 MODERNA, INC. By: /s/ Shannon Thyme Klinger Shannon Thyme Klinger Chief Legal Officer